Published in Oncotarget on May 15, 2014
The role of the AMOP domain in MUC4/Y-promoted tumour angiogenesis and metastasis in pancreatic cancer. J Exp Clin Cancer Res (2016) 1.43
The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol (2015) 1.11
MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer (2014) 1.00
Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas. Genes Dis (2015) 0.99
The role of adipose-derived stem cells in breast cancer progression and metastasis. Stem Cells Int (2015) 0.90
WIP1 stimulates migration and invasion of salivary adenoid cystic carcinoma by inducing MMP-9 and VEGF-C. Oncotarget (2015) 0.88
Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression. Oncotarget (2015) 0.86
Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer. Onco Targets Ther (2016) 0.85
The role and potential mechanisms of LncRNA-TATDN1 on metastasis and invasion of non-small cell lung cancer. Oncotarget (2016) 0.85
By activating matrix metalloproteinase-7, shear stress promotes chondrosarcoma cell motility, invasion and lung colonization. Oncotarget (2015) 0.85
Antimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via Suppressing MMP2/9 by Blocking NF-κB and ERK/MAPK Signaling Pathways. PLoS One (2015) 0.85
Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion. Cancer Inform (2015) 0.84
CCL2-CCR2 axis promotes metastasis of nasopharyngeal carcinoma by activating ERK1/2-MMP2/9 pathway. Oncotarget (2016) 0.81
Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2. Cancer Biol Ther (2015) 0.81
Obesity-associated NLRC4 inflammasome activation drives breast cancer progression. Nat Commun (2016) 0.79
Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression. Oncotarget (2016) 0.79
Plantamajoside, a potential anti-tumor herbal medicine inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of matrix metalloproteinase-9 and -2. BMC Cancer (2015) 0.79
MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. Aging (Albany NY) (2016) 0.78
LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells. Oncogene (2015) 0.78
miR-199a-5p suppresses human bladder cancer cell metastasis by targeting CCR7. BMC Urol (2016) 0.77
CITED2 Modulates Breast Cancer Metastatic Ability through Effects on IKKα. Mol Cancer Res (2016) 0.77
Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci (Landmark Ed) (2015) 0.76
MMP3-mediated tumor progression is controlled transcriptionally by a novel IRF8-MMP3 interaction. Oncotarget (2015) 0.76
Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness. Oncotarget (2016) 0.76
Development of high-affinity and high-specificity inhibitors of metalloproteinase 14 through computational design and directed evolution. J Biol Chem (2017) 0.76
Tumor Detection at 3 Tesla with an Activatable Cell Penetrating Peptide Dendrimer (ACPPD-Gd), a T1 Magnetic Resonance (MR) Molecular Imaging Agent. PLoS One (2015) 0.75
Anti-RhoC siRNAs inhibit the proliferation and invasiveness of breast cancer cells via modulating the KAI1, MMP9, and CXCR4 expression. Onco Targets Ther (2017) 0.75
Sequential measurements of serum matrix metalloproteinase 9 to monitor chemotherapy responses in patients with advanced non-small-cell lung cancer. Onco Targets Ther (2016) 0.75
MMP7 interacts with ARF in nucleus to potentiate tumor microenvironments for prostate cancer progression in vivo. Oncotarget (2016) 0.75
Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment. Neoplasia (2016) 0.75
Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway. Int J Biol Sci (2016) 0.75
Alginate-embedded HuH-7 cells increase MMP-9 and reduce OCLN expression in vitro. Cancer Cell Int (2017) 0.75
Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours. BMC Cancer (2016) 0.75
Curcumin induces G2/M cell cycle arrest and apoptosis of head and neck squamous cell carcinoma in vitro and in vivo through ATM/Chk2/p53-dependent pathway. Oncotarget (2017) 0.75
Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing using Multifunctional pRNA Nanoparticles. ACS Nano (2016) 0.75
Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. J Cell Biochem (2017) 0.75
Loss of Kaiso expression in breast cancer cells prevents intra-vascular invasion in the lung and secondary metastasis. PLoS One (2017) 0.75
MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells. Oncogenesis (2017) 0.75
Inherent aggressive character of invasive and non-invasive cells dictates the in vitro migration pattern of multicellular spheroid. Sci Rep (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
Breast cancer metastasis: markers and models. Nat Rev Cancer (2005) 9.93
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol (2004) 6.83
The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res (2008) 5.69
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol (2003) 4.16
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J (2010) 3.68
Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell (2008) 3.56
Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 3.32
GOBO: gene expression-based outcome for breast cancer online. PLoS One (2011) 2.81
Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One (2010) 2.67
Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49
New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta (2011) 2.22
Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer (2006) 2.20
The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev (2007) 2.07
Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.07
Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci (2006) 1.96
CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol (1998) 1.93
Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer (2008) 1.89
Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res (2008) 1.88
Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res (2004) 1.88
Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem (2005) 1.83
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res (2010) 1.81
DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med (2011) 1.81
A refined molecular taxonomy of breast cancer. Oncogene (2011) 1.78
MMPs as therapeutic targets--still a viable option? Semin Cell Dev Biol (2007) 1.78
Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res (2011) 1.71
Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis (1999) 1.70
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat (2011) 1.68
Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med (2012) 1.67
Recent advances in MMP inhibitor design. Cancer Metastasis Rev (2006) 1.66
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol (2012) 1.64
Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer (2007) 1.63
Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer (2001) 1.55
Genome profiling of ERBB2-amplified breast cancers. BMC Cancer (2010) 1.53
Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol (2008) 1.51
Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord (2007) 1.51
Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev (2003) 1.45
Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc Natl Acad Sci U S A (2009) 1.45
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol (2008) 1.37
Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res (2005) 1.36
Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem (2010) 1.31
Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med (2011) 1.29
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol (2004) 1.29
Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett (2007) 1.27
Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One (2011) 1.27
Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res (2006) 1.26
Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat (2013) 1.21
Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat (2004) 1.18
The development of endocrine therapy for women with breast cancer. Cancer Treat Rev (2012) 1.17
Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition? Biochim Biophys Acta (2009) 1.15
Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem (2008) 1.15
Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors. Protein Sci (2007) 1.08
Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res (2011) 1.06
Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol (2012) 1.04
Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins. J Biol Chem (2003) 1.03
Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J Biol Chem (2004) 1.01
Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat Med (2011) 0.99
Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem (2012) 0.97
Homology with vesicle fusion mediator syntaxin-1a predicts determinants of epimorphin/syntaxin-2 function in mammary epithelial morphogenesis. J Biol Chem (2009) 0.95
PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol Cancer Res (2012) 0.93
Unraveling hidden regulatory sites in structurally homologous metalloproteases. J Mol Biol (2013) 0.93
A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim Biophys Acta (2006) 0.93
Growth of lung cancer cells in three-dimensional microenvironments reveals key features of tumor malignancy. Integr Biol (Camb) (2011) 0.91
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res (2004) 0.89
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol (2002) 0.88
PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). PLoS One (2012) 0.85
Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes. PLoS One (2013) 0.84
A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4β1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells. J Biol Chem (2012) 0.83
The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation (2002) 4.64
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol (2004) 2.93
MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits. Nat Cell Biol (2012) 2.61
Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A (2006) 2.41
Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. Ann Surg (2012) 2.35
Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol (2008) 2.18
Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.07
Laminin and biomimetic extracellular elasticity enhance functional differentiation in mammary epithelia. EMBO J (2008) 1.74
Association between mammographic density and age-related lobular involution of the breast. J Clin Oncol (2010) 1.70
Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis (2008) 1.69
Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med (2012) 1.67
TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res (2011) 1.65
Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci U S A (2004) 1.53
Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord (2007) 1.51
Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood (2009) 1.50
Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene (2004) 1.42
Change in cell shape is required for matrix metalloproteinase-induced epithelial-mesenchymal transition of mammary epithelial cells. J Cell Biochem (2008) 1.41
Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer. Cancer Res (2012) 1.41
Clinical characteristics of breast cancers in African-American women with benign breast disease: a comparison to the surveillance, epidemiology, and end results program. Breast J (2014) 1.39
A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis (2002) 1.37
Genomewide significant linkage to recurrent, early-onset major depressive disorder on chromosome 15q. Am J Hum Genet (2004) 1.32
Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.32
Tumor suppressor function of Rab25 in triple-negative breast cancer. Int J Cancer (2010) 1.28
Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol (2011) 1.27
Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol (2009) 1.23
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A (2002) 1.22
WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Mol Cancer Res (2012) 1.21
Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res (2010) 1.21
Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol (2012) 1.20
Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer (2007) 1.18
High affinity small protein inhibitors of human chymotrypsin C (CTRC) selected by phage display reveal unusual preference for P4' acidic residues. J Biol Chem (2011) 1.18
Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res (2009) 1.16
Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia (2003) 1.15
Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) (2014) 1.13
TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther (2013) 1.11
Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One (2012) 1.10
Host epithelial geometry regulates breast cancer cell invasiveness. Proc Natl Acad Sci U S A (2012) 1.09
Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia (2008) 1.08
Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin. J Biol Chem (2007) 1.07
ROS-induced epithelial-mesenchymal transition in mammary epithelial cells is mediated by NF-kB-dependent activation of Snail. Oncotarget (2014) 1.07
Screening for hazardous alcohol use and depressive symptomatology among HIV-infected patients in Nigeria: prevalence, predictors, and association with adherence. J Int Assoc Physicians AIDS Care (Chic) (2010) 1.05
Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. Cancer Res (2008) 1.05
Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat (2011) 1.05
Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail's pace. Int J Biochem Cell Biol (2007) 1.04
Matrix compliance regulates Rac1b localization, NADPH oxidase assembly, and epithelial-mesenchymal transition. Mol Biol Cell (2012) 1.04
Snail1, Snail2, and E47 promote mammary epithelial branching morphogenesis. EMBO J (2011) 1.03
Development of a mouse model for assessing fatigue during chemotherapy. Comp Med (2011) 1.02
Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia (2011) 1.02
Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo. Cytotherapy (2013) 1.01
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat (2009) 1.00
Sclerosing adenosis and risk of breast cancer. Breast Cancer Res Treat (2014) 0.99
The 19-amino acid insertion in the tumor-associated splice isoform Rac1b confers specific binding to p120 catenin. J Biol Chem (2010) 0.99
Non-classical export of epimorphin and its adhesion to alphav-integrin in regulation of epithelial morphogenesis. J Cell Sci (2007) 0.99
Pseudoangiomatous stromal hyperplasia and breast cancer risk. Ann Surg Oncol (2010) 0.98
NF-kappaB links oestrogen receptor signalling and EMT. Nat Cell Biol (2007) 0.97
Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin. J Biol Chem (2010) 0.97
Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem (2012) 0.97
New model of macrophage acquisition of the lymphatic endothelial phenotype. PLoS One (2012) 0.95
The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity. Biochem J (2011) 0.95
Homology with vesicle fusion mediator syntaxin-1a predicts determinants of epimorphin/syntaxin-2 function in mammary epithelial morphogenesis. J Biol Chem (2009) 0.95
Extracellular matrix proteins regulate epithelial-mesenchymal transition in mammary epithelial cells. Differentiation (2013) 0.94
Involvement of hnRNP A1 in the matrix metalloprotease-3-dependent regulation of Rac1 pre-mRNA splicing. J Cell Biochem (2012) 0.94
Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues. Breast Cancer Res Treat (2011) 0.94
PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol Cancer Res (2012) 0.93
Growth of lung cancer cells in three-dimensional microenvironments reveals key features of tumor malignancy. Integr Biol (Camb) (2011) 0.91
Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline. Ann Vasc Surg (2010) 0.91
The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin. J Biol Chem (2009) 0.91
Aortopathy in the 7q11.23 microduplication syndrome. Am J Med Genet A (2014) 0.89
miR-200c at the nexus of epithelial-mesenchymal transition, resistance to apoptosis, and the breast cancer stem cell phenotype. Breast Cancer Res (2011) 0.89
Benign breast disease and the risk of subsequent breast cancer in African American women. Cancer Prev Res (Phila) (2012) 0.89
E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B. J Mol Cell Biol (2013) 0.89
Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer. Cancer Prev Res (Phila) (2011) 0.88
Malignant mammary cells acquire independence from extracellular context for regulation of estrogen receptor alpha. Clin Cancer Res (2004) 0.88
Immune cell quantitation in normal breast tissue lobules with and without lobulitis. Breast Cancer Res Treat (2014) 0.86
Molecular profile and proliferative responses of rat lymphatic endothelial cells in culture. Lymphat Res Biol (2006) 0.86
Proliferation and polarity in breast cancer: untying the Gordian knot. Cell Cycle (2005) 0.86
PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). PLoS One (2012) 0.85
Retrospective comparison of patient outcomes after in-person and telephone results disclosure counseling for BRCA1/2 genetic testing. Fam Cancer (2010) 0.85
TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure. J Cereb Blood Flow Metab (2013) 0.85
Expression of a novel marker, Ubc9, in squamous cell carcinoma of the head and neck. Head Neck (2009) 0.85
Regulation of tumor angiogenesis by the local environment. Front Biosci (Landmark Ed) (2010) 0.84
Stromal-cell-derived factor (SDF) 1-alpha in combination with BMP-2 and TGF-β1 induces site-directed cell homing and osteogenic and chondrogenic differentiation for tissue engineering without the requirement for cell seeding. Cell Tissue Res (2012) 0.84
Flat epithelial atypia and risk of breast cancer: A Mayo cohort study. Cancer (2015) 0.84
An integrated model of the transcriptome of HER2-positive breast cancer. PLoS One (2013) 0.84